influenza
Vaccines · 2007–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| influenza vaccine, adjuvanted Active immunisation against influenza in adults aged 65 years and above. The submission included two purposes: an increased price premium for Fluad (adjuvanted… | Jul 2019 | Not recommended | none received |
| influenza vaccine adjuvanted quadrivalent and trivalent Active immunisation against influenza in adults aged 65 years and above. | Jul 2019 | Not recommended | none received |
| inactivated trivalent influenza vaccine (split virion) Active immunisation against influenza disease caused by influenza virus types A and B in persons aged ≥65 years. | Nov 2019 | Recommended with restriction | input received Diabetes Australia |
| inactivated trivalent influenza vaccine (split virion), high dose Active immunisation against influenza disease caused by influenza virus types A and B for adults aged 65 years and older. | Jul 2018 | Not recommended | 1 individuals Lung Foundation Australia · Diabetes Australia |
| inactivated trivalent influenza vaccine (split virion) Active immunisation against influenza disease caused by influenza virus subtypes A and type B in adults aged 65 years and older. | Mar 2018 | Recommended | 2 individuals |
| quadrivalent influenza vaccine Active immunisation against influenza disease caused by influenza A and B subtype viruses in all individuals listed on the National Immunisation Program,… | Jul 2015 | Recommended with restriction | none received |
| trivalent influenza vaccine Annual vaccination for Aboriginal and Torres Strait Islander children aged 6 months to 5 years to prevent influenza and reduce disease burden in this high-risk… | Jul 2014 | Recommended | no section in document |
| influenza vaccine, intradermal Universal vaccination against influenza of all persons aged 65 years and older. | Jul 2009 | Recommended with restriction | no section in document |
| influenza vaccine Prevention of influenza caused by Influenza Virus, Types A and B in all Australians aged 50 years and older. | Nov 2007 | Not recommended | no section in document |
| influenza vaccine Prevention of influenza caused by Influenza Virus, Types A and B in persons aged 50 years and older. | Nov 2007 | Not recommended | no section in document |
Who spoke
Diabetes Australia · Lung Foundation Australia
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| baloxavir marboxilBaloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal) | TA1135 | terminated | 2026-02 |
| amantadine oseltamivir and zanamivirAmantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | recommended | 2009-02 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| influenza virus haemagglutininAFLURIA QUAD - Inactivated Quadrivalent Influenza vaccine (split virio | 2002 | 32 |
| baloxavir marboxilXOFLUZA baloxavir marboxil 20 mg film-coated tablet blister pack | 2020 | 3 |
| influenza virusFLUMIST influenza virus vaccine 10,000,000 FFU/strain (0.2mL) nasal sp | 2016 | 2 |
| influenza haemagglutinin recombinantFLUBLOK trivalent recombinant influenza vaccine, Influenza haemaggluti | 2021 | 2 |
| peramivirRAPIVAB peramivir 200 mg / 20 mL concentrate for intravenous infusion | 2018 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.